Linked Life Data

16609040

Source:http://linkedlifedata.com/resource/pubmed/id/16609040

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7 Pt 1
pubmed:dateCreated
2006-4-12
pubmed:abstractText
To characterize interactions between the heat shock protein 90 antagonist 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase 1/2 inhibitor PD184352 in Bcr/abl(+) leukemia cells sensitive and resistant to imatinib mesylate.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/17-(allylamino)-17-demethoxygeldanam..., http://linkedlifedata.com/resource/pubmed/chemical/17-(dimethylaminoethylamino)-17-deme..., http://linkedlifedata.com/resource/pubmed/chemical/2-(2-chloro-4-iodophenylamino)-N-cyc..., http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzamides, http://linkedlifedata.com/resource/pubmed/chemical/Benzoquinones, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Fusion Proteins, bcr-abl, http://linkedlifedata.com/resource/pubmed/chemical/Lactams, Macrocyclic, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines, http://linkedlifedata.com/resource/pubmed/chemical/Quinones, http://linkedlifedata.com/resource/pubmed/chemical/Rifabutin, http://linkedlifedata.com/resource/pubmed/chemical/imatinib
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2239-47
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:16609040-Antineoplastic Agents, pubmed-meshheading:16609040-Apoptosis, pubmed-meshheading:16609040-Benzamides, pubmed-meshheading:16609040-Benzoquinones, pubmed-meshheading:16609040-Cell Line, Tumor, pubmed-meshheading:16609040-Cell Proliferation, pubmed-meshheading:16609040-Cell Survival, pubmed-meshheading:16609040-Dose-Response Relationship, Drug, pubmed-meshheading:16609040-Drug Resistance, Neoplasm, pubmed-meshheading:16609040-Drug Screening Assays, Antitumor, pubmed-meshheading:16609040-Drug Synergism, pubmed-meshheading:16609040-Enzyme Inhibitors, pubmed-meshheading:16609040-Fusion Proteins, bcr-abl, pubmed-meshheading:16609040-Humans, pubmed-meshheading:16609040-Lactams, Macrocyclic, pubmed-meshheading:16609040-Leukemia, pubmed-meshheading:16609040-Piperazines, pubmed-meshheading:16609040-Pyrimidines, pubmed-meshheading:16609040-Quinones, pubmed-meshheading:16609040-Rifabutin, pubmed-meshheading:16609040-Sensitivity and Specificity, pubmed-meshheading:16609040-Structure-Activity Relationship, pubmed-meshheading:16609040-Time Factors, pubmed-meshheading:16609040-Tumor Cells, Cultured
pubmed:year
2006
pubmed:articleTitle
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
pubmed:affiliation
Department of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural